OneDigital Investment Advisors LLC Sells 28,984 Shares of Pfizer Inc. (NYSE:PFE)

OneDigital Investment Advisors LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 19.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 123,254 shares of the biopharmaceutical company’s stock after selling 28,984 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Pfizer were worth $3,567,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in shares of Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer during the 2nd quarter valued at about $29,000. Quarry LP purchased a new stake in Pfizer during the 2nd quarter valued at about $31,000. Financial Connections Group Inc. purchased a new stake in Pfizer during the 2nd quarter valued at about $34,000. Finally, ESL Trust Services LLC purchased a new stake in Pfizer during the 1st quarter valued at about $37,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $24.80 on Friday. The firm has a 50 day moving average price of $28.71 and a 200-day moving average price of $28.65. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market capitalization of $140.54 billion, a price-to-earnings ratio of 33.51, a PEG ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the business earned ($0.17) earnings per share. The business’s revenue was up 31.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.77%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday. They set an “underperform” rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.